Tag: Baby powder lawyer

Woman Wins Big On Talcum Powder Ovarian Cancer Claim

A Jury Granted More Than $70M In A J&J Baby Powder  Ovarian Cancer Lawsuit.

A California woman has been awarded more than $70 million  in a claim that Johnson and Johnson’s baby powder gave  her ovarian cancer.

“We are pleased the jury did the right thing. They once again reaffirmed the need for Johnson & Johnson to warn the public of the ovarian cancer risk associated with its product,” Jim Onder, an attorney for the plaintiff, advised The Associated Press.

“We deeply sympathize with the women and families impacted by ovarian cancer,” Carol Goodrich, a spokeswoman with Johnson & Johnson, said in a statement. “We will appeal today’s verdict because we are guided by the science, which supports the safety of Johnson’s Baby Powder.”

Is Baby Powder Safe?

It is now known that use of talc products can  increase a women’s risk of ovarian cancer.

The International Agency for Research on Cancer advises that the product is “possibly carcinogenic.” The National Toxicology Program, made up of parts of a few distinctive government organizations, has not completely inspected talc.

 

 

Latest Research on Ovarian Cancer

The Talcum Powder Lawsuit Helpline is more then just a network of experienced Talcum Powder Lawsuit Attorneys. We offer ovarian cancer resources and updates that are found online. Below you will find some of the latest research on ovarian cancer. It is now known, that the manufacturers knew that there was a potential link between ovarian cancer and the use of Talcum Powder and Baby Powder. The jury knew it when they gave the family of a talcum powder- ovarian cancer victim $72 million.

We found this page on the latest research and offer it to our followers. We hope this helps.

Ovarian Cancer – Latest Research
Approved by the Cancer.Net Editorial Board, 04/2015

Doctors are working to learn more about ovarian cancer, ways to prevent it, how to best treat it, and how to provide the best care to people diagnosed with this disease. The following areas of research may include new options for patients through clinical trials. Always talk with your doctor about the diagnostic and treatment options best for you.

Screening For Ovarian Cancer

There are no currently effective screening methods for the general population. A screening method that estimates a woman’s risk of ovarian cancer by using her age and the results of a yearly CA-125 blood test holds promise for detecting early-stage ovarian cancer. An international study is looking into the role of serial CA-125 screening for ovarian cancer. As explained in Diagnosis, CA-125 is a substance called a tumor marker that is found in higher levels in women with ovarian cancer.

In 2012, the U.S Preventative Services Task Force released a statement saying that for the general population of women with no symptoms, screening for ovarian cancer is not helpful and may lead to harm. However, women at high risk for ovarian cancer due to family history or with a BRCA mutation(s) (see Risk Factors) are recommended to have screening with CA-125 blood tests and transvaginal ultrasound. This approach has not been proven to improve survival or detect cancers at an earlier and more curable stage.

Targeted Therapy For Ovarian Cancer

Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.

Some targeted therapy is directed towards specific genes that might be found with abnormalities in certain types of epithelial ovarian cancer. For this purpose, ovarian cancer is divided into two groups:  type I and type II.  Type II cancers are the more typical high grade serous cancers, for which standard chemotherapy has been most effective. These tumors typically are diagnosed at later stages and have mutations in TP53 and BRCA genes in the tumor.  Other mutations are rarely seen.

The BRCA mutation, even if only found in the tumor and not in the blood, may increase the effectiveness of a certain classes of drugs such as PARP inhibitors (see below).  Type I tumors include the more rare types of ovarian cancer including low grade serous, endometrioid, clear cell, and mucinous cancers.  These tumors have a variety of mutations including KRAS, BRAF, PI3KCA and PTEN, which have implications for targeted treatment. Clinical trials in these groups are ongoing.

Anti-Angiogenesis Inhibitors For Ovarian Cancer

Drugs called anti-angiogenesis inhibitors block the action of a protein called vascular endothelial growth factor (VEGF). These drugs have been shown to increase the cancer’s response to treatment and delay the time it takes for the cancer to return. VEGF promotes angiogenesis, which is the formation of new blood vessels. Because a tumor needs nutrients delivered by blood vessels to grow and spread, the goal of anti-angiogensis therapies is to “starve” the tumor. Bevacizumab (Avastin), an antibody which binds VEGF and prevents it from being active, has been shown to be effective in ovarian cancer.  FDA approval was recently given in the United States for its use in combination with selected chemotherapy for patients with platinum resistant recurrence.
PARP Inhibitors For Ovarian Cancer

Another class of drugs, called PARP inhibitors, are being evaluated for ovarian cancer.  These drugs act on DNA repair in cancer cells, making it difficult for them to replicate.  The BRCA genes (BRCA1 and BRCA2) are also normally involved in DNA repair, and a mutation in these genes interfere with this pathway function.  PARP inhibitors make it particularly difficult for cells that otherwise have a BRCA mutation to grow and divide.

The PARP inhibitor olaparib (Lynparza) has received FDA approval in the United States for recurrent disease in patients who have the inherited BRCA mutation and who have received three or more lines of chemotherapy.  In the supporting study of 137 patients with a BRCA mutation, 34% of patients experienced shrinkage in tumor for an average of 7.9 months. A very small number of patients developed secondary hematologic (blood) cancers after use of these drugs. Studies are currently underway with other PARP inhibitors, which do not all require the inherited BRCA mutation. These are being tested to see if they can keep the cancer from coming back after chemotherapy. The potential benefits and risks of PARP therapy should be discussed with your doctor.
Many other new targeted treatments are also now in clinical trials. Increasingly, doctors are learning about each patient’s individual tumor’s biology through direct molecular testing. This information may be useful in matching patients with a clinical trial for a specific targeted therapy.  Learn more about the basics of targeted therapy.

Immunotherapy For Ovarian Cancer

Immunotherapy is usually designed to boost the body’s natural defenses to fight the cancer. It uses materials made either by the body or in a laboratory to bolster, target, or restore immune system function. Researchers are currently examining whether drugs called checkpoint inhibitors may boost the immune system’s ability to destroy cancer cells.  Examples of these drugs target CTLA4 or PD-1 and have recently been shown to cause shrinkage in other cancer types such as melanoma, as well as having some activity in patients with ovarian cancer.

Cancer vaccines are another type of immunotherapy currently being tested for ovarian cancer.  In addition, some approaches called “adoptive cell therapy” take killer T cells found as part of the immune system in an individual patient and grow them in the laboratory, train them to attack certain targets such as MUC 16 (CA125) that is found on any ovarian cancer cells, and them give them back intravenously to the patient.  This approach has been tried in patients with hematologic cancers using other targets with some early success, and clinical trials are now opening for ovarian cancer.  Learn more about the basics of immunotherapy.

Hormone Therapy For Ovarian Cancer

Research is underway about the role of estrogen, androgens, and other hormones in ovarian cancer treatment. For treatment of recurrent or later-stage ovarian cancer,  the use of tamoxifen (Nolvadex, Soltamax), aromatase inhibitors, and enzalutamide (Xtandi), a blocker of the androgen receptor, is being considered.

Gene Therapy For Ovarian Cancer

One new area of research is discovering how damaged genes in ovarian cancer cells can be corrected or replaced. Researchers are studying the use of specially designed viruses that carry normal genes into the core of cancer cells and then replace the defective genes with the functional ones.

Supportive Care For Ovarian Cancer

Clinical trials are underway to find better ways of reducing symptoms and side effects of current ovarian cancer treatments, in order to improve a woman’s comfort and quality of life.

We will continue to search the net for ovarian cancer  information to help our clients. Our goal is to offer information that may help

 

Talcum Powder – Ovarian Cancer Link Alert

Talcum Powder Lawsuit Helpline  alerts women who didn’t know of the possible link between   Talcum powder product use  on the pelvic area and ovarian cancer. Talcum powder lawyers claim that if talcum powder is used for years the particles can travel to the fallopian tubes and the ovaries. They can stay there for years and cause irritation which eventually can result in cancer cells. Ovarian cancer rates are highest in women aged 55-64 years. This is the exact age group that Talcum powder was marketed to when they were  teenagers and young women.

Johnson & Johnson is now  facing more than 1,000 lawsuits from women claiming they  knew that the talc in its Baby Powder and Shower to Shower products was linked to ovarian cancer when used in the genital area. They did not warn anyone of this. Both products were marketed extensively  for feminine hygiene. . A 1988 ad for Shower to Shower said “just a sprinkle a day keeps odor away.” Others told women: “Your body perspires in more places than just under your arms.”

Is Talcum Powder  Johnson and Johnson’s next horror for women?  1000’s of women are still suffering from their vaginal mesh products. The Talcum Powder Lawsuit Helpline receives dozens of calls every day from women who feel their ovarian cancer is from use of these Talcum Powder products. Juries have started to award female victims and families who have lost loved ones compensation.

What Are The Symptoms Of Ovarian Cancer?

Pain in the pelvis or abdomen
Bloating in the abdomen
Urinary urgency
Urinary frequency
Constipation or diarrhea
Feeling full quickly while eating
Having difficulty eating
Vaginal bleeding or other discharge that is different than normal
Back pain
If you have any of these symptoms, talk to your doctor.

What Is Talcum Powder?

Talcum powder is made from talc or   hydrated magnesium silicate which occurs naturally as a mineral in formations like soapstone. For over 120 years, Johnson & Johnson has marketed talcum powder around the world as a baby powder and for adults to absorb sweat in products like Shower to Shower.

Johnson and Johnson has  targeted women to increase sales. “Want to feel cool, smooth and dry? It’s as easy as taking powder from a baby,” was the text in a  Johnson & Johnson ad from the 1960s.

In the 1970s, the first studies emerged showing that talc was deeply embedded into ovarian cancers. Johnson & Johnson introduced corn starch alternatives but it continued to offer talc-based products. In 2014 Johnson & Johnson’s annual talcum powder sales were estimated at $374 million.

The Research Is In On Talcum Powder

The World Health Organization reports that talc is “possibly carcinogenic to humans.” Talc is banned in Europe.

If you believe your diagnosis of ovarian cancer is due to use of Johnson’s Baby Powder or Shower To Shower speak to one of our Talcum powder lawyers.

Spread The Word On Talcum Powder Lawsuits and Dangers

Do you know someone who has ovarian cancer. Tell them about the dangers of Talcum powder.